Trust BOTOX® for your patients with post-stroke spasticity (PSS)
Early identification should affect course of intervention in PSS, which will be key for patients' outcomes.11
Importance of early identification
PSS: post-stroke spasticity.
Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The BOTOX® Summary of Product Characteristics can be found here
By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
Date of preparation: June 2025. UK-BTX-250064.